RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bionano Genomics - Stock

Bionano Genomics EBIT 2024

Bionano Genomics EBIT

-92.38 M USD

Ticker

BNGO

ISIN

US09075F1075

WKN

A2JRLZ

In 2024, Bionano Genomics's EBIT was -92.38 M USD, a -33.04% increase from the -137.97 M USD EBIT recorded in the previous year.

The Bionano Genomics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

Bionano Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bionano Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bionano Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bionano Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bionano Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bionano Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bionano Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bionano Genomics’s growth potential.

Bionano Genomics Revenue, Profit, and EBIT History

DateBionano Genomics RevenueBionano Genomics EBITBionano Genomics Net Income
2029e192.91 M undefined0 undefined41.6 M undefined
2028e141.51 M undefined-4.07 M undefined12.96 M undefined
2027e103.66 M undefined-29.32 M undefined-8.87 M undefined
2026e75.8 M undefined-53.66 M undefined-23.19 M undefined
2025e48.3 M undefined-70.62 M undefined-76.61 M undefined
2024e38.85 M undefined-92.38 M undefined-118.44 M undefined
202336.12 M undefined-137.97 M undefined-232.49 M undefined
202227.8 M undefined-129.9 M undefined-132.6 M undefined
202117.98 M undefined-75.6 M undefined-72.44 M undefined
20208.5 M undefined-37.05 M undefined-41.11 M undefined
201910.13 M undefined-25.88 M undefined-29.82 M undefined
201812 M undefined-20.42 M undefined-18.5 M undefined
20179.51 M undefined-22.62 M undefined-23.37 M undefined
20166.79 M undefined-21.17 M undefined-18.85 M undefined

Bionano Genomics stock margins

The Bionano Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bionano Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bionano Genomics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bionano Genomics's sales revenue. A higher gross margin percentage indicates that the Bionano Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bionano Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bionano Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bionano Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bionano Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bionano Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bionano Genomics Margin History

Bionano Genomics Gross marginBionano Genomics Profit marginBionano Genomics EBIT marginBionano Genomics Profit margin
2029e26.49 %0 %21.56 %
2028e26.49 %-2.88 %9.16 %
2027e26.49 %-28.28 %-8.55 %
2026e26.49 %-70.8 %-30.59 %
2025e26.49 %-146.21 %-158.62 %
2024e26.49 %-237.82 %-304.89 %
202326.49 %-382.01 %-643.74 %
202221.4 %-467.27 %-476.98 %
202121.52 %-420.47 %-402.89 %
202032.59 %-435.88 %-483.65 %
201933.17 %-255.48 %-294.37 %
201827.42 %-170.17 %-154.17 %
201736.49 %-237.85 %-245.74 %
201647.28 %-311.78 %-277.61 %

Bionano Genomics Aktienanalyse

What does Bionano Genomics do?

Bionano Genomics Inc. is a biotechnology company specializing in the development of DNA analysis systems. The company is headquartered in California and was founded in 2003. History: The company was originally established as a research group at the University of California, San Diego. Over the years, the group has evolved into a leading company in DNA analysis and genome analysis. Business model: Bionano Genomics Inc. has a business model based on the analysis and processing of DNA sequences. The company offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Products: The company has introduced a range of products that help revolutionize genomics. One of Bionano Genomics' most important products is the Saphyr system. This system uses optical DNA mapping technology to make DNA sorting and mapping more efficient. The Saphyr system can contribute to improving and accelerating genomic research in various industries. Another product of the company is the COVID-19 assay. This assay is used in the detection of COVID-19. It is used in the laboratory and is fast and accurate. Divisions: Bionano Genomics offers its products and services in three different business areas: genomic research, clinical research, and diagnostics. Genomic research: Bionano Genomics works closely with research institutes and companies to perform DNA analysis. The Saphyr system is used to analyze DNA samples and conduct genome studies. With this technology, it has become possible to visualize large genomic regions to gain insights into complex genomic changes and rearrangements, such as those related to cancer. Clinical research: The company works closely with clinicians to conduct clinical studies and diagnose diseases. The Saphyr system can help in the investigation of structural DNA variants associated with specific diseases such as autism, schizophrenia, and epilepsy. Diagnostics: Bionano Genomics also offers services for the diagnosis of genetic disorders. The company provides tests that examine genetic markers and indicators to make an accurate diagnosis. The company also offers genetic counseling services to help families affected by genetic diseases. Overall, Bionano Genomics has the potential to change the way we study, diagnose, and treat genetic diseases. The company has already formed partnerships with several industry leaders and research institutions to advance its research. Bionano Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Bionano Genomics's EBIT

Bionano Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Bionano Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Bionano Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Bionano Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Bionano Genomics Stock

How much did Bionano Genomics achieve in EBIT for the current year?

In the current year, Bionano Genomics has achieved an EBIT of -92.38 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Bionano Genomics.

How has the EBIT of Bionano Genomics developed in recent years?

The EBIT of Bionano Genomics has increased by -33.041% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Bionano Genomics?

The EBIT of Bionano Genomics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Bionano Genomics pay?

Over the past 12 months, Bionano Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionano Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bionano Genomics?

The current dividend yield of Bionano Genomics is .

When does Bionano Genomics pay dividends?

Bionano Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bionano Genomics?

Bionano Genomics paid dividends every year for the past 0 years.

What is the dividend of Bionano Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bionano Genomics located?

Bionano Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bionano Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bionano Genomics from 6/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/23/2024.

When did Bionano Genomics pay the last dividend?

The last dividend was paid out on 6/23/2024.

What was the dividend of Bionano Genomics in the year 2023?

In the year 2023, Bionano Genomics distributed 0 USD as dividends.

In which currency does Bionano Genomics pay out the dividend?

The dividends of Bionano Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bionano Genomics

Our stock analysis for Bionano Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionano Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.